According to The Insight Partners' research, the Asia Pacific Knee Implants Market was valued at US$ 2,632.3 Million in 2024 and is expected to reach US$ 4,111.2 Million by 2031, registering a CAGR of 6.7% from 2025 to 2031.
Advancing innovations to elevate product effectiveness and user uptake and elective backlog and increased waiting times reshaping surgeries are among the critical factors attributed to drive the Asia Pacific knee implants market growth.
The rapid pace of product innovation, regulatory approvals, and advances in surgical technique to improve outcomes, reduce complications, and make knee replacement more accessible are catalyzing the adoption rate of knee implants. In late 2024, Zimmer Biomet obtained US FDA Premarket Approval for its Oxford Cementless Partial Knee system, making it the only cementless partial knee implant approved in the US. This implant offers better fixation and efficiency in the operating room, based on over 20 years of clinical experience and more than 300,000 procedures worldwide. Likewise, Zimmer Biomet's Persona SoluTion porous plasma spray (PPS) femur component recently received FDA 510(k) clearance (December 2024) as an alternative for patients with sensitivities to bone cement or metal, offering a fully cementless fixation when used with compatible tibia and patella components. Another example is the Globus Medical "ExcelsiusFlex + ACTIFY 3D Total Knee System," which was cleared via FDA 510(k) in July 2024. It combines robotic navigation and a 3D implant system with porous lattice interfaces conducive to cementless fixation and improved anatomic fit. Also, materials innovation, such as the newly FDA-cleared Activit E polyethylene with Vitamin E antioxidant for Exactech's Truliant knee system (August 2025), seeks to improve durability and wear performance without needing gamma sterilization (which can degrade certain properties). These innovations enhance surgeon and patient confidence, reduce revision rates, permit use in broader patient populations, and potentially reduce perioperative morbidity. Therefore, regulatory approvals of newer implants, improved materials, cementless fixation, robotic assistance, and more customized or partial knee solutions are driving the knee implant market expansion.
On the contrary, the long waiting times and access delays in public health systems hamper the growth of the Asia Pacific knee implants market.
Asia Pacific Knee Implants Market Segmentation Analysis:
- By Type of Procedures, the Asia Pacific Knee Implants Market is segmented into Total Knee Replacement, Partial Knee Replacement, and Revision Knee Replacement. The Total Knee Replacement segment is projected to expand at a CAGR of 6.6% during 2025 - 2031.
- By Implant Type, the Asia Pacific Knee Implants Market is segmented into Fixed Bearing Prosthesis and Mobile Bearing Prosthesis. The Fixed Bearing Prosthesis segment is projected to expand at a CAGR of 7.0% during 2025 - 2031.
- By Material, the Asia Pacific Knee Implants Market is segmented into Cemented and Non-Cemented. The Cemented segment is projected to expand at a CAGR of 7.0% during 2025 - 2031.
- By End User, the Asia Pacific Knee Implants Market is segmented into Hospitals, Orthopedic Clinics, Others, and Ambulatory Surgical Centers. The Hospitals segment is projected to expand at a CAGR of 7.2% during 2025 - 2031.
By country, the Asia Pacific Knee Implants Market is categorized into China, Japan, India, Australia, South Korea, and the Rest of APAC. China is projected to expand at a CAGR of 7.5% during 2025 - 2031.
Key players operating in the Knee Implants Market are MicroPort Scientific Corp, Medtronic Plc, Stryker Corp, Zimmer Biomet Holdings Inc, Smith & Nephew Plc, Conmed Corp, Exactech Inc, B. Braun Melsungen AG, Enovis Corp, amd Medacta Group SA, among others.
- In September 2025, MicroPort Orthopedics Inc. announced that it had launched the Evolution® Tibial Cones, the latest addition to the Evolution® Revision Knee System. This innovative product line is designed to address the significant challenges faced by surgeons during revision total knee arthroplasty (TKA) procedures, particularly in managing metaphyseal bone loss.
- In August 2024, Enovis, an innovation-driven medical technology growth company, announced the expansion of its EMPOWR Revision Knee system to include EMPOWR Cones. The addition of the stackable tibial, femoral, and diaphyseal cones increases options for treating bone defects, creating a comprehensive portfolio to support complex revision needs. The FDA cleared use of the EMPOWR Cones with EMPOWR Revision Knee earlier this year
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com